Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET

Company Participants

Robert Andrade - Chief Financial Officer

Rostislav Raykov - Chief Executive Officer

Adrian Haigh - Chief Operating Officer

Conference Call Participants

Chase Knickerbocker - Craig-Hallum Capital Group

David Nierengarten - Wedbush Securities

Operator

Good morning, ladies and gentlemen and welcome to the Fennec Pharmaceuticals Second Quarter 2023 Earnings and Corporate Update Conference Call. [Operator Instructions] As a reminder, today's conference call is being recorded.

Now, I would like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.

Robert Andrade

Thank you, operator and good morning, everyone. We are delighted that you could join us today for Fennec Pharmaceuticals' second quarter 2023 earnings conference call. During which, we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is Rosty Raykov, our Chief Executive Officer; and our newly appointed Chief Operating Officer, Adrian Haigh.

Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.

This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. And with that, I will now turn this call over to Rosty Raykov.

Rostislav Raykov

Thank you, Robert and good morning, everyone. We'll be discussing our recent progress as we have achieved many significant milestones over the past several months. The focus of today's call is to review updates on the ongoing launch efforts underway for PEDMARK in the U.S. and discuss our global opportunities, including the recent approval in Europe.

Further, we will detail our second quarter financial results, all of which were outlined in our earnings press release issued this morning prior to this call. As a reminder, PEDMARK is the first and only FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss in pediatric patients, one month of age and older with localized non-metastatic solid tumors. The availability of PEDMARK is ushered in a critical breakthrough for the pediatric oncology community which was enthusiastically awaiting a rigorously tested and FDA-approved option to safely increase the potential long-term quality of life of these young patients.